Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LIBERTY: Liquid Biopsy to Diagnose and Monitor Central Nervous System (CNS) Involvement in High-risk B Cell Non-Hodgkin Lymphoma

NCT06090162 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT06090162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06090162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LIBERTY: Liquid Biopsy to Diagnose and Monitor Central Nervous System (CNS) Involvement in High-risk B Cell Non-Hodgkin Lymphoma
Lead sponsor
Swiss Cancer Institute
Phase
Not applicable
Overall status
Active, not recruiting
Start date
March 12, 2024
Completion date
December 31, 2026
Enrollment
64 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma, b cell